A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)

Trial Profile

A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Mar 2017

At a glance

  • Drugs Onalespib (Primary) ; Crizotinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Astex Pharmaceuticals
  • Most Recent Events

    • 11 Jul 2016 Planned End Date changed from 1 Dec 2016 to 1 Mar 2017.
    • 11 Jul 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2016.
    • 07 Jun 2016 Interim Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top